Anti-inflammatory activities of 1-cinnamoyl-2-methyl-5-methoxy-3-indolylacetic acid (cinmetacin).
D000085:Acetates; D000208:Acute Disease; D000700:Analgesics / Q000627:therapeutic use; D000818:Animals; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D001168:Arthritis / Q000188:drug therapy; D001831:Body Temperature / Q000187:drug effects; D002908:Chronic Disease; D002934:Cinnamates / Q000627:therapeutic use* / Q000633:toxicity; D004353:Drug Evaluation, Preclinical; D004361:Drug Tolerance; D004487:Edema / Q000188:drug therapy; D004890:Erythema / Q000188:drug therapy; D006471:Gastrointestinal Hemorrhage / Q000188:drug therapy; D006099:Granuloma / Q000188:drug therapy; D006168:Guinea Pigs; D006821:Hyaluronoglucosaminidase / Q000494:pharmacology; D007211:Indoles / Q000627:therapeutic use* / Q000633:toxicity; D051379:Mice; D010538:Peritonitis / Q000188:drug therapy; D011489:Protein Denaturation; D011817:Rabbits; D051381:Rats
D000085:Acetates; D000700:Analgesics; D000893:Anti-Inflammatory Agents; D002934:Cinnamates; D007211:Indoles; D006821:Hyaluronoglucosaminidase